| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441156 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
Significant changes in tumour morphology, grade, hormone receptors and HER2 status occur following NACT. We recommend testing on residual invasive carcinoma. A switch from negative to positive status warrants offering endocrine/trastuzumab-based therapy to this group of patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Renu Gahlaut, Aneliese Bennett, Hiba Fatayer, Barbara J. Dall, Nisha Sharma, Galina Velikova, Tim Perren, David Dodwell, Mark Lansdown, Abeer M. Shaaban,